Active substance
Misoprostol
- SFDA 1
- US FDA 5
- Health Canada 3
- US price lines 2
- NHS prices 1
- WHO EML 2
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Cytotec | 200 µg | Tablet · Oral use | 28 Blister | SAR 40.35 | NCE · Prescription | Pfizer Limited | Valid |
Indications — CHI Daman Drug Formulary
DYSPEPSIA; MATERNAL AND CHILD HEALTHCARE- POSTPARTUM HEMORRHAGE, INDUCTION OF LABOR, MISCARRIAGE
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CYTOTEC | 0.2MG; 0.1MG | tablet · oral | PFIZER | Prescription | 27 Dec 1988 |
| MISOPROSTOL | 0.1MG; 0.2MG | tablet · oral | ANI PHARMS | Prescription | 10 Jul 2002 |
| MISOPROSTOL | 0.1MG; 0.2MG | tablet · oral | ACQ PHARMA | Prescription | 2 Jul 2019 |
| MISOPROSTOL | 0.1MG; 0.2MG | tablet · oral | NOVEL LABS INC | Discontinued | 25 Jul 2012 |
| MISOPROSTOL | 0.1MG; 0.2MG | tablet · oral | MICRO LABS | Discontinued | 17 Oct 2022 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| JAMP MISOPROSTOL | 02545284 | 200 MCG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| MISOPROSTOL | 02244022 | 100 MCG | TABLET · ORAL | AA PHARMA INC |
| MISOPROSTOL | 02244023 | 200 MCG | TABLET · ORAL | AA PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | MISOPROSTOL 100 MCG TABLET | $0.4645 | per EA | 23 Sep 2026 |
| US NADAC | MISOPROSTOL 200 MCG TABLET | $0.71894 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Misoprostol 200microgram tablets | £10.03 | 60 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 22.3. Uterotonics · core
Unspecified obstetric condition; Postpartum haemorrhage
Local > Vaginal > tablet: 25 µg | Oral > Solid: 200 µg - 22.4. Medicines for medical abortion · complementary
Spontaneous abortion, incomplete, without complication
Oral > Solid > tablet: 200 µg
Safety signals and safety-related labeling changes
- US FDA 21 Nov 2024 ARTHROTEC — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 28 Feb 2018 CYTOTEC — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Use in Specific Populations
Combinations containing Misoprostol
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.